Parameters of Haemostasis during Acute Venous Thrombosis

Summary

Underlying disorders of the coagulation system such as inhibitor deficiencies or decreased fibrinolysis are common in patients suffering from venous thrombosis. They may lead to the necessity of a lifelong prophylaxis. Prompt diagnosis is obviously to the patients benefit. We investigated 22 patients suffering from venous thromboses for the inhibitors antithrombin III (ATIII), protein C, and protein S during the first 8 to 12 days after admission to hospital and in addition after withdrawal from anticoagulant treatment after several months. At the day of admission ATIII and protein C levels were comparable to those several months later, but after 2 days they shifted downward or upward, respectively. Protein S did not shift during the period of hospitalisation, but was initially slightly lower than several months later. For inhibitors the day of admission to hospital is most suitable to take the samples. About 50% of the patients still had elevated activation markers (prothrombin fragments F1+2, thrombin-antithrombin complex TAT, and D-dimers) after several months.

• References

• 1 Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic diseasecritical evaluation of laboratory investigation. Thromb Haemost 1992; 68 (01) 7-13
• 2 Hirsch J, Piovella F, Pini M. Congenital antithrombin III deficiency. Am J Med 1989; 87: 3B-37S
• 3 Bertina RM, Broekmans AW, Krommenhoek-van Es C, Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost 1984; 51: 1-5
• 4 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088
• 5 Comp PC. Overview of the hypercoagulable states. Semin Thromb Haemost 1990; 16: 158-161
• 6 Joist JH. Hypercoagulability: introduction and perspective. Semin Thromb Haemost 1990; 16: 151-117
• 7 Vikydal R, Kominger C, Kyrle PA, Niessner H, Pabinger I, Thaler E, Lechner K. The prevalence of hereditary antithrombin-III deficiency in patients with a history of venous thromboembolism. Thromb Haemost 1985; 54 (04) 744-745
• 8 Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterocygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59 (01) 18-22
• 9 Brockmans AW, Linden van der IK, Jansen-Koeter V, Beilina KM. Prevalence of protein C (PC) and protein S (PS) deficiency in patients with thrombotic disease. Thromb Res 1986; suppl (Suppl. 04) 135 (Abstr.)
• 10 Griffin JN, Evatt B, Zimmerman TS, Kleiss AJ. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 11 Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-1072
• 12 Di Seipio RG, Hermodson MA, Yates SG, Davie LW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-706
• 13 Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antitrombin III. Lancet 1977; 581-584
• 14 Taberncro D, Espana F, Vicente V, Estelles A, Gilabert J, Aznar J. Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment. Thromb Hacmost 1990; 63 (03) 380-382
• 15 Andcrsson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Wilhelmsson S. Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34: 333-340
• 16 Goto S, Hada S, Kawai Y, Watanabc K, Abe S, Takahashi E, Hori S, Jkeda Y. Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction. Cardiology 1992 80 3-4 252-256
• 17 Petersen KR, Sidclmann J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gyneco 1993 168: 32-38
• 18 Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 1992 167: 1184-1191
• 19 Granata A, Sobhrio GA, D’Arrigo F, Barillari M, De-Luca P, Egitto M, Granese D, Pulle C, Trimarchi F. Changes in the plasma levels of protein C and S in young women on low-dose oestrogen oral contraceptives. Clin Exp Obstet Gynecol 1991 18 (01) 9-12
• 20 Fletcher B, Taylor JR, Protein S. C4b binding protein, and the hyper-coagulable state. J Lab Clin Med 1992; 119: 596-597